Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21299732 | 0.84 | KIF11 (0.47) | PTAFR | |
| SCHEMBL105809 | 0.82 | NPC1 (0.41) | NPC1 | |
| SCHEMBL67978 | 0.80 | NISCH (0.46) | NOTUMNPC1 | |
| SCHEMBL20410845 | 0.79 | NPC1 (0.39) | NPC1 | |
| SCHEMBL18045369 | 0.78 | CHRM1 (0.44) | — | |
| Carbimide SCHEMBL29055881 | 0.76 | NPC1 (0.37) | NPC1 | |
| SCHEMBL10520530 | 0.76 | KCNH2 (0.38) | NPC1 | |
| SCHEMBL27260114 | 0.76 | NISCH (0.46) | NPC1 | |
| SCHEMBL23054974 | 0.75 | KCNH2 (0.37) | NPC1 | |
| SCHEMBL1338566 | 0.75 | NISCH (0.47) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999131-B | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-06-28 | — | — | CN | disclosed |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| WO-2015054120-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054120-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-05-15 | — | — | US | disclosed |
| WO-2013091696-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-27 | — | — | WO | disclosed |
| EP-2468735-A1 | Synthesis of intermediates for preparing anacetrapib and derivates thereof | LEK Pharmaceuticals d.d. (SI) | 2012-06-27 | — | — | EP | disclosed |
| WO-2007136672-A2 | SYNTHESIS OF A BIARYL SYNTHETIC INTERMEDIATE | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | CYP2B6, CYP4B1, CIAPIN1 | NOTUM 1216/4885CNR2 482/4885IDO1 801/4885 |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | NOTUM 1391/4885CNR2 802/4885IDO1 498/4885 |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | RUVBL2, RUVBL1, CYP2W1 | NOTUM 1391/4885CNR2 802/4885IDO1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.